CoreWeave insider 10b5-1 sales total 625,000 shares in August

Rhea-AI Filing Summary

CoreWeave, Inc. (CRWV) insider sale notice: The filing reports a proposed sale of 375,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $34,642,500 based on the filing. The shares were acquired as founders' shares on 11/13/2017. The filer discloses recent Rule 10b5-1 sales in the past three months: 250,000 shares sold 08/19/2025 for gross proceeds of $22,926,475, and 375,000 shares sold 08/19/2025 for gross proceeds of $34,389,712.50. The notice includes the standard representation that the seller does not possess undisclosed material nonpublic information and flags reliance on a trading plan if applicable.

Positive

• Use of Rule 10b5-1 plans for recent sales, indicating prearranged transactions
• Brokered execution via Morgan Stanley Smith Barney, showing orderly planned disposal

Negative

• Large proposed sale size of 375,000 shares valued at $34,642,500
• Recent significant sales in past three months totaling 625,000 shares for gross proceeds above $57 million, increasing share supply

Insights

Securities Analyst

TL;DR: Large insider sales totaling hundreds of thousands of shares were executed or proposed, representing significant liquidity from an insider.

The filing documents a proposed sale of 375,000 founder shares valued at approximately $34.6 million and recent 10b5-1 sales in August 2025 aggregating 625,000 shares with combined gross proceeds above $57 million. From a market-impact perspective, these are sizable transactions relative to typical insider activity and could increase available float in the short term. The use of Rule 10b5-1 programs for recent sales suggests at least some sales were preplanned, which reduces the likelihood they reflect ad hoc reactions to material undisclosed information. Investors should note this is a disclosure of intent and completed recent sales, not a change in company guidance or operations.

Corporate Governance Expert

TL;DR: Insider is selling founder shares under broker arrangement; reliance on 10b5-1 plans is disclosed.

The notice shows founder-originated shares being sold and also documents 10b5-1 plan executions earlier in August 2025. From a governance perspective, transparent reporting and the 10b5-1 framework align with best practices for reducing appearance of opportunistic insider trading. However, the scale of the sales is material in dollar terms and warrants monitoring for potential signaling effects about insider liquidity needs or portfolio rebalancing. The filing does not indicate any regulatory or disclosure concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	375000	34642500.00	370470348	08/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/13/2017	Founders Shares	Issuer			375000	11/13/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for BRANNIN MCBEE 290 W Mt. Pleasant Ave. Livingston NJ 07039	Common	08/19/2025	250000	22926475.00
10b5-1 Sales for BRANNIN J. MCBEE 2022 IRR TRUST 290 W Mt. Pleasant Ave. Livingston NJ 07039	Common	08/19/2025	375000	34389712.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for CoreWeave (CRWV) report being sold?

The filing reports a proposed sale of 375,000 common shares (founders' shares) and discloses recent 10b5-1 sales of 250,000 and 375,000 shares executed on 08/19/2025.

What is the aggregate market value of the proposed CRWV sale?

The proposed sale of 375,000 shares has an aggregate market value reported as $34,642,500.

Were the shares originally acquired as founder shares?

Yes. The securities to be sold were acquired as founders' shares on 11/13/2017.

Did the filing disclose prior sales by the same person recently?

Yes. The filing lists two 10b5-1 sales on 08/19/2025 totaling 625,000 shares with gross proceeds of $22,926,475 and $34,389,712.50 respectively.

Which broker is handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, New York, NY.